Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03625648 · ClinicalTrials.gov registry record · Phase 4
Pentoxifylline in Diabetic Kidney Disease
A Phase 4 study of Diabetic Kidney Disease, sponsored by VA Office of Research and Development.
- Active
- Registry status
- Phase 4
- Development phase
- 2,376
- Enrollment target
- 20
- Study locations
NCT03625648: Active Phase 4 study of Diabetic Kidney Disease, sponsored by VA Office of Research and Development.
NCT03625648 is a Phase 4 study of Diabetic Kidney Disease that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 2,376 participants, below the 5,086-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03625648, a Phase 4 study of Diabetic Kidney Disease, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,376 participants
- Enrollment target
- 20
- Study locations
Study Summary
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Primary Outcome
ESRD will be defined as need for chronic dialysis or renal transplantation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pentoxifylline
Study Locations (20)
California
- VA Loma Linda Healthcare System, Loma Linda, CA - Loma Linda
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
Florida
- Bay Pines VA Healthcare System, Pay Pines, FL - Bay Pines
- North Florida/South Georgia Veterans Health System, Gainesville, FL - Gainesville
- James A. Haley Veterans' Hospital, Tampa, FL - Tampa
Missouri
- Harry S. Truman Memorial, Columbia, MO - Columbia
- Kansas City VA Medical Center, Kansas City, MO - Kansas City
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO - St Louis
Arizona
- Phoenix VA Health Care System, Phoenix, AZ - Phoenix
Arkansas
- Central Arkansas Veterans Healthcare System, Little Rock, AR - Little Rock
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Illinois
- Edward Hines Jr. VA Hospital, Hines, IL - Hines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,376 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2030-07-08 |
| Phase | Phase 4 |
What the registry record for NCT03625648 still lists
NCT03625648 is an interventional study that assigns participants to a tested intervention. Its 2,376 participants enrollment target places it among the larger protocols in the corpus, below the 5,086-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03625648 names 20 study sites across 14 states, led by California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT03625648 about?
NCT03625648 is a clinical study titled "Pentoxifylline in Diabetic Kidney Disease". Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a stud...
What is the current status of trial NCT03625648?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2,376 participants. The study started on 2019-11-18. Estimated completion is 2030-07-08.
What conditions does trial NCT03625648 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease.
What interventions are being tested in trial NCT03625648?
The interventions under investigation include: Placebo (DRUG), Pentoxifylline (DRUG).
Who is sponsoring clinical trial NCT03625648?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03625648 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03625648's enrollment target sits among peer trials
2,376 3rd of 23 higher than 21 of 23 other Diabetic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Dosimetry of Tc-99m-Tilmanocept
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05868421 · 2,376 participants · NA
Veteran Social Support for Enhancing Use of Smoking Cessation Treatment
- NCT06747494 · 2,396 participants · NA
General vs Spinal in Total Joint Arthroplasty (TJA)
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI